• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Correction to: Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study.对《缓释胍法辛治疗成人注意力缺陷/多动障碍的安全性和有效性：一项开放标签、长期、3期扩展研究》的勘误
BMC Psychiatry. 2020 Dec 22;20(1):596. doi: 10.1186/s12888-020-02965-7.
2
Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents.胍法辛缓释剂：一种治疗儿童和青少年注意缺陷多动障碍的新型药物。
Clin Ther. 2013 Nov;35(11):1778-93. doi: 10.1016/j.clinthera.2013.09.005. Epub 2013 Oct 16.
3
A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.一项关于缓释胍法辛治疗儿童和青少年注意力缺陷/多动障碍的随机、双盲、安慰剂对照研究。
Pediatrics. 2008 Jan;121(1):e73-84. doi: 10.1542/peds.2006-3695.
4
Pharmacokinetics and pharmacodynamics of guanfacine extended release in adolescents aged 13-17 years with attention-deficit/hyperactivity disorder.胍法辛缓释剂在 13-17 岁注意缺陷多动障碍青少年中的药代动力学和药效学。
Clin Pharmacol Drug Dev. 2014 Jul;3(4):252-61. doi: 10.1002/cpdd.124. Epub 2014 May 17.
5
Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.盐酸胍法辛缓释片治疗儿童及青少年注意力缺陷多动障碍的长期安全性和有效性
J Child Adolesc Psychopharmacol. 2009 Jun;19(3):215-26. doi: 10.1089/cap.2008.0080.
6
Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder.缓释胍法辛简介及其在治疗注意力缺陷多动障碍中的潜力。
Neuropsychiatr Dis Treat. 2015 May 28;11:1359-70. doi: 10.2147/NDT.S65735. eCollection 2015.
7
Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD.盐酸胍法辛缓释片用于儿童和青少年注意力缺陷多动障碍的长期开放标签扩展研究。
CNS Spectr. 2008 Dec;13(12):1047-55. doi: 10.1017/s1092852900017107.
8
Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHD.胍法辛缓释剂治疗注意缺陷多动障碍患儿和青少年的长期安全性和疗效。
Eur Child Adolesc Psychiatry. 2018 Oct;27(10):1283-1294. doi: 10.1007/s00787-018-1113-4. Epub 2018 Feb 13.
9
A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.一项随机、安慰剂对照试验研究胍法辛缓释剂治疗青少年注意缺陷多动障碍。
J Am Acad Child Adolesc Psychiatry. 2015 Nov;54(11):916-25.e2. doi: 10.1016/j.jaac.2015.08.016. Epub 2015 Sep 15.
10
Supplementary guanfacine hydrochloride as a treatment of attention deficit hyperactivity disorder in adults: A double blind, placebo-controlled study.盐酸胍法辛作为成人注意缺陷多动障碍的治疗：一项双盲、安慰剂对照研究。
Psychiatry Res. 2016 Feb 28;236:136-141. doi: 10.1016/j.psychres.2015.12.017. Epub 2015 Dec 17.

引用本文的文献

1
52-Week Open-Label Safety and Tolerability Study of Centanafadine Sustained Release in Adults With Attention-Deficit/Hyperactivity Disorder.52周开放标签研究：盐酸西他那非缓释片在成人注意力缺陷/多动障碍患者中的安全性和耐受性
J Clin Psychopharmacol. 2025;45(5):454-462. doi: 10.1097/JCP.0000000000002020. Epub 2025 Jul 2.

本文引用的文献

1
Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study.胍法辛缓释剂在成人注意缺陷多动障碍中的安全性和疗效：一项开放标签、长期、3 期扩展研究。
BMC Psychiatry. 2020 Oct 2;20(1):485. doi: 10.1186/s12888-020-02867-8.

Correction to: Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study.

作者信息

Iwanami Akira, Saito Kazuhiko, Fujiwara Masakazu, Okutsu Daiki, Ichikawa Hironobu

机构信息

Department of Psychiatry, Showa University School of Medicine, 6-11-11 Kita Karasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.

Aiiku Counselling Office, Aiiku Research Institute, Imperial Gift Foundation Boshi-Aiiku-Kai, Tokyo, Japan.

出版信息

BMC Psychiatry. 2020 Dec 22;20(1):596. doi: 10.1186/s12888-020-02965-7.

DOI:10.1186/s12888-020-02965-7
PMID:33353538
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7756943/
Abstract
摘要